A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults
A Single-center, Randomized, Active-controlled, Parallel-group, Open-label, Phase I Study to Evaluate Safety and Immunogenicity of Single Injection of LBVD or Eupenta Co-administered With Imovax Polio in Healthy Adults
Sponsor: LG Chem
This PHASE1 trial investigates Diphtheria and Haemophilus Influenzae Type b Infection and is currently completed. LG Chem leads this study, which shows 9 recorded versions since 2017 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2019 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 4 earlier versions
-
Jun 2018 — Sep 2019 [monthly]
Completed PHASE1
-
May 2018 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Oct 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Aug 2017 — Oct 2017 [monthly]
Recruiting PHASE1
First recorded
Jul 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- LG Chem
For direct contact, visit the study record on ClinicalTrials.gov .